about
Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human TissueGood quality of life in former Buruli ulcer patients with small lesions: long-term follow-up of the BURULICO trialLong term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial.The gamma-glutamyl transpeptidase to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: 'The gamma-glutamyl transpeptiKinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans diseaseInfection with Mansonella perstans Nematodes in Buruli Ulcer Patients, GhanaA severe case of Buruli ulcer disease with pleural effusionsMycobacterium ulcerans DNA not detected in faecal samples from Buruli ulcer patients: results of a pilot study.Research and capacity building for control of neglected tropical diseases: the need for a different approach.Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring.Assessing and strengthening African universities' capacity for doctoral programmes.Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an Assay using punch biopsy specimens for diagnosis of Buruli ulcer.Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana.Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy.Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine.Psychometric properties of the participation scale among former buruli ulcer patients in Ghana and BeninPersisting social participation restrictions among former Buruli ulcer patients in Ghana and Benin.Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response.Effectiveness of routine BCG vaccination on buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo.Genetic diversity of PCR-positive, culture-negative and culture-positive Mycobacterium ulcerans isolated from Buruli ulcer patients in Ghana.Buruli ulcer control in a highly endemic district in Ghana: role of community-based surveillance volunteers.Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer diseasePain Associated with Wound Care Treatment among Buruli Ulcer Patients from Ghana and BeninAssessment and Treatment of Pain during Treatment of Buruli UlcerLoop-Mediated Isothermal Amplification for Laboratory Confirmation of Buruli Ulcer Disease-Towards a Point-of-Care Test.Simple, Rapid Mycobacterium ulcerans Disease Diagnosis from Clinical Samples by Fluorescence of Mycolactone on Thin Layer ChromatographyHelicobacter pylori Infection Is Associated with Higher CD4 T Cell Counts and Lower HIV-1 Viral Loads in ART-Naïve HIV-Positive Patients in Ghana.Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana.Emerging aspects of Buruli ulcer.Genetic Susceptibility and Predictors of Paradoxical Reactions in Buruli UlcerFormer Buruli Ulcer Patients' Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management.Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression.Metabolomic profiles delineate mycolactone signature in Buruli ulcer disease.A re-evaluation of the origin of hepatitis C virus genotype 2 in West Africa.Buruli ulcer: emerging from obscurity.Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxidesDynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humansBuruli ulcer disease: prospects for a vaccine.
P50
Q28472261-1F63D22A-216E-4194-A4E7-17F5A71EBC3EQ28540627-1E897B1C-55A5-42A0-8237-5850C171554FQ28540814-5781AA63-EBA2-4183-9A94-219424E9981BQ28603383-19D5F9B7-71E6-4E7A-91F1-38B798FF6ECEQ33613484-8A739FAA-D608-47E6-8882-D9D4BE004585Q33678688-FF71C6C7-24FF-4BA2-A5ED-D5B1E2FCCEC1Q33778730-8C123993-176C-49A9-BA59-68CB4D84DA66Q33900802-35D81318-7651-448F-96D9-54A2F8D40098Q33927463-01F05D46-DE64-4EFE-BD23-DB2281DE1502Q33938119-E30D647E-01CE-4735-8274-4FDA2AB2467AQ33980141-91D9C7D3-D0FC-4C64-A60D-D9E070C65AAAQ34022976-AC3C905A-E4A1-421B-B61F-F4097F3D5F8AQ34041583-A0327F8B-3E5E-4330-8C53-FD574ADAB380Q34108789-9949AED8-C22F-4760-8216-1C34989E22C6Q34120399-E1C6968C-7A9D-4F8A-A871-7D4296CFE1C6Q34395892-C2FB5D1B-42CE-46CE-95C2-12AA6AA78ADAQ34492614-7F975738-F80A-4C9D-BC4E-65CA4246B334Q34505238-A21FF4DB-1B61-4AA0-B5B1-DBD0953D9A2AQ34505664-0202FCCD-E34B-48D7-B3D3-65AB0E1A6D82Q34602038-CD247F03-5804-4574-B593-6C5FC28A2ECFQ34875651-1B1BEB2F-B10D-449B-9B2C-5B9AA1C39C6FQ35092680-291E163B-C654-4E42-94B0-A9F4FEFBA0B6Q35140526-2A14CD43-67D9-45B8-80B9-1425720949B3Q35145483-2F50A73B-A4BA-406D-AF87-01F963A97387Q35648325-290CA568-B558-46EC-9C5E-078384E7FAE8Q35786460-91C9BEB3-300A-4BEF-9D39-822A342A929CQ35840888-7C8CD420-ABEE-4ADF-B92E-3BEF594838E4Q35846128-04E9B113-62E6-49E8-A1DD-D3E2E26E9363Q35850519-403998ED-66D8-4A60-9FE3-60CD098DE8BCQ35858002-531B2E64-EC4C-4E14-8464-00FEAAEB2EFBQ35917186-83BA34AC-B70D-4016-BB29-2651821100E9Q35994923-87415042-AF05-4F0F-BAD3-EB1FE621C441Q36235570-A83B628F-C909-4D70-ABAB-DD8A1493BEDBQ36291527-528CF8CD-BF1D-43AA-BCC0-8270ED86D0E3Q36346380-A6FE10F1-FA25-43BD-A88C-FB8E6621748AQ36376619-6A374D2A-F9E1-4FB5-97AF-54B8554CA3F0Q36497273-45145B09-745C-4910-BA42-AD88562C18BFQ36670940-EF86AF4D-DF26-438C-A4F7-756127233B87Q37051036-CDA2A6BE-BCDE-4D7A-90CB-368CA5EB282EQ37387041-3C09EE43-B662-4AD4-AC6A-79B8F7E90AB2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Richard Phillips
@ast
Richard Phillips
@en
Richard Phillips
@es
Richard Phillips
@nl
Richard Phillips
@sl
type
label
Richard Phillips
@ast
Richard Phillips
@en
Richard Phillips
@es
Richard Phillips
@nl
Richard Phillips
@sl
altLabel
Richard Odame Phillips
@en
prefLabel
Richard Phillips
@ast
Richard Phillips
@en
Richard Phillips
@es
Richard Phillips
@nl
Richard Phillips
@sl
P106
P1412
P1960
bmq1tzMAAAAJ
P21
P31
P496
0000-0001-8992-0222